
Verizon raises annual profit forecast over premium plans and tax reform
Shares of the company rose 3.5% on Monday as it also surpassed Wall Street estimates for June-quarter sales and profit, thanks to a 2.2% rise in wireless service revenue.
The telecom major has launched price-lock promotions and broadband-wireless bundles to retain users as competition intensifies from AT&T and T-Mobile, as well as broadband providers Comcast and Charter.
Verizon is also benefiting from favorable U.S. tax reform that allows companies to immediately write off the full cost of certain new equipment, finance chief Tony Skiadas said.
He estimated the legislation will boost free cash flow by $1.5 billion to $2 billion this year, prompting Verizon to raise its forecast for the metric to between $19.5 billion and $20.5 billion, up from $17.5 billion to $18.5 billion previously.
The company now expects 2025 adjusted profit to grow between 1% and 3%, compared with 0% to 3% previously.
Verizon pays the highest cash taxes among major U.S. telecoms, Wells Fargo analysts said earlier this month, adding the tax law will provide a big financial boost to the industry.
Shares of AT&T and T-Mobile were both up 2.3%.
However, Verizon posted a surprise drop of 9,000 monthly bill-paying wireless subscribers in the second quarter, reeling from user churn after price hikes in January. Analysts polled by FactSet were expecting an increase of 13,000 subscribers.
To drive growth, Verizon and its rivals have been bulking up on fiber-optic assets that can tap growing consumer data use.
Verizon in May won approval from the U.S. telecom regulator for its $20 billion acquisition of fiber-optic internet provider Frontier, after it agreed to end its diversity programs.
The sharper focus on internet services helped it posted 293,000 broadband net additions in the second quarter.
Overall, Verizon reported revenue of $34.5 billion, beating estimates of $33.74 billion, according to data compiled by LSEG. Its adjusted earnings per share of $1.22 also beat estimates.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
AI and Automation Integration Elevates Laboratory Informatics Demand
The North America laboratory informatics market, valued at USD 1.62 billion in 2024, is set to grow at a CAGR of 4.30% to USD 2.48 billion by 2034. Growth is fueled by cloud-based LIMS, AI, and automation. Pharma and biotech sectors leverage informatics for efficiency, boosting the market with strategic partnerships. North American Laboratory Informatics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "North America Laboratory Informatics Market Report and Forecast 2025-2034" has been added to offering. The North America laboratory informatics market was valued at USD 1.62 billion in 2024, driven by accelerating demand for cloud-based platforms. It is projected to grow at a CAGR of 4.30% from 2025 to 2034, reaching USD 2.48 billion by 2034. Informatics solutions, including LIMS, ELN, SDMS, and CDS, enhance data accuracy, compliance, and workflow automation in industries like pharmaceuticals and biotechnology. Innovations in cloud computing, AI, and automation are transforming laboratory data management by improving decision-making, regulatory compliance, and productivity. Market Growth Drivers and Trends Adoption of unified digital platforms is propelling market growth. The integration of LIMS and ELN functionalities enhances data security and collaboration. For example, eLabNext rebranded its key products into a centralised Digital Lab Platform in October 2024, aligning with market shifts toward streamlined management. The preference for advanced ELN systems is positively impacting market size. TeselaGen Biotechnology launched an enhanced ELN in December 2024, improving productivity and data management in biotech and pharmaceutical research. Global collaborations are strengthening market value. LabWare engaged with biopharma entities in Ireland in June 2024, facilitating knowledge exchange and technological advancements in LIMS adoption. Integration of AI and Automation The demand for AI-driven automation is elevating market demand. Funding initiatives support development in automated chemical laboratories, accelerating innovation and efficiency. By reducing manual errors, AI integrations boost LIMS and ELN system adoption, driving long-term market growth. Emerging Trends Cloud-Based LIMS: With significant IT sector contributions to GDP, cloud solutions are becoming essential for efficiency and compliance. Partnerships such as Revvity Signals Software with Scitara drive innovations in cloud-based platforms for R&D. AI and Automation: Initiatives like Scialog and LabVantage Solutions' integration of mixed reality demonstrate a shift towards AI-driven laboratory processes, enhancing efficiency and research competitiveness. Strategic Partnerships: Collaborations, such as those by LabVantage, are fuelling regulatory compliance and workflow automation, offering growth opportunities in laboratory informatics. Market Segmentation and Key Players: The market is segmented by product, delivery mode, component, end user, and region, with LIMS leading due to its pivotal role in sample management and workflow automation. Cloud solutions are preferred for scalability, while software advancements drive component value. Pharmaceutical companies hold the largest share, driven by stringent regulatory demands and R&D investments. Their adoption of informatics solutions enhances drug development and compliance. Major companies include Serum Institute of India, CSL Limited, Bharat Biotech, and CanSino Biologics, further shaping market dynamics with innovative solutions and global strategies. Region Analysis The United States dominates the market with strong R&D investments and digitalisation, while Canada shows growth due to government initiatives and cloud platform adoption. Both countries advance laboratory informatics with investments in data management and AI solutions. Conclusion The North America laboratory informatics market continues to grow, driven by technological advancements and strategic initiatives. The emphasis on AI, automation, and cloud solutions fosters efficiency and competition in the biotech, pharmaceutical, and research sectors. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $1.62 Billion Forecasted Market Value (USD) by 2034 $2.48 Billion Compound Annual Growth Rate 4.3% Regions Covered North America For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Laboratory Informatics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
$515M Bet on Musk, AI, and Space: Glade Brook Goes All-In While Others Retreat
Glade Brook Capital Partners just pulled in $515 million for its fourth fund and it's placing its bets on the edge of what's next: AI, space, defense, and fintech. The firm, which already holds stakes in SpaceX, Stripe, and Elon Musk's Neuralink, plans to double down on late-stage tech startups navigating some of the most volatile capital markets in recent memory. Founder Paul Hudson didn't sugarcoat the conditions, calling it the most challenging fundraising environment he's seen in his career even as the fund ended up oversubscribed. Despite the headwinds, Glade Brook is leaning into momentum. It's already backing Musk's xAI and Artisan AI, signaling a clear tilt toward artificial intelligence. That comes on top of a portfolio that includes ramping fintech player Ramp and previously backed giants like Uber (NYSE:UBER) and Airbnb (NASDAQ:ABNB). And in a move that tracks closely with broader market appetite, the firm is betting that innovation in complex, capital-intensive sectors like AI and defense could offer asymmetric upside if timed right. Tesla (NASDAQ:TSLA) remains part of the broader Musk-aligned orbit Glade Brook is exposed to, adding even more edge to its late-stage tech focus. Their 2021 fund a $430 million vehicle reportedly ranks in the top 5% of its vintage, according to private Cambridge Associates data. While past performance doesn't guarantee future returns, it does suggest Glade Brook knows how to play late-stage cycles. In a market where many VCs are stuck in wait-and-see mode, Glade Brook appears to be playing offense betting that when the next wave breaks, it'll be the firms already in position that ride it the farthest. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data